Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis
Advanced Science · 2024
DOI: 10.1002/advs.202304342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ning Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhe…. Hauptthemen laut MEDLINE: B7-H1 Antigen, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy targeting PD‐L1 is still ineffective for a wide variety of tumors with high unpredictability. Deploying combined immunotherapy with alternative targeting is practical to overcome this therapeutic resistance. Here, the deficiency of serine‐threonine kinase STK24 is observed in tumor cells causing substantial attenuation of tumor growth in murine syngeneic models, a process relying on cytotoxic CD8 + T and NK cells. Mechanistically, STK24 in tumor cells associates with and directly phosphorylates AKT at Thr21, which promotes AKT activation and subsequent PD‐L1 induction. Deletion or inhibition of STK24, by contrast, blocks IFN‐γ‐mediated PD‐L1 expression. Various murine models indicate that in vivo silencing of STK24 can significantly enhance the efficacy of the anti‐PD‐1 blockade strategy. Elevated STK24 levels are observed in patient specimens in multiple tumor types and inversely correlated with intratumoral infiltration of cytotoxic CD8 + T cells and with patient survival. The study collectively identifies STK24 as a critical modulator of antitumor immunity, which engages in AKT and PD‐L1/PD‐1 signaling and is a promising target for combined immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
- Department of Clinical Laboratory, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310058, China.
- Westlake Laboratory of Life Sciences and Biomedicine, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, 310024, China.
- Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
- Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
ORCID-Profile: Xiaojian Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, N., Jiang, Y., Li, M., Wang, H., Pan, J., Tang, Y., Xie, S., Xu, Y., Li, X., Zhou, X., Xu, P., Lin, W., & Wang, X. (2024). Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis. Advanced Science. https://doi.org/10.1002/advs.202304342
Vancouver
Wang N, Jiang Y, Li M, Wang H, Pan J, Tang Y, et al. Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis. Advanced Science. 2024. doi:10.1002/advs.202304342
BibTeX
@article{Wang2024,
author = {Wang, Ning and Jiang, Yu and Li, Mengjie and Wang, Haofei and Pan, Jie and Tang, Yang and Xie, Shaofang and Xu, Yunyang and Li, Xu and Zhou, Xuefei and Xu, Pinglong and Lin, Wenlong and Wang, Xiaojian},
title = {Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202304342}
}
EUVIMED